Length-dependent diabetic polyneuropathy does not show any trend towards improvement, and either relentlessly progresses or remains relatively stable over a number of years. Conversely ...
This could help to lower the risk of insulin resistance and the chance of developing diabetes. Marijuana use may also lead to weight gain in some people because it can increase food cravings. Often ...
Caficrestat is under clinical development by Applied Therapeutics and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData, Phase III drugs for Diabetic Peripheral ...
Background It is believed that genetic factors play a role in the development and severity of neural injury among people with distal symmetrical polyneuropathy (DSP), because some genes are involved ...
The number of people with diabetes has shot up during the last few decades, with over 422 million people worldwide affected. Peripheral neuropathy is nerve damage that can result from various ...
For SUI and pain associated with diabetic peripheral neuropathy, duloxetine has not demonstrated equivalence or superiority to existing therapies. The adverse effects of duloxetine are similar to ...
Dr. Lucas Brown, DAOM, LAc, spoke with Studio 512 about how his clinic, Rosedale Acupuncture & Wellness, can help with chronic pain conditions, including peripheral neuropathy. You treat a lot of ...
Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study.
Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData, Phase III drugs for Diabetic Peripheral ...
Ageing and diabetes are closely linked, but understanding the condition can help you take control. Discover the symptoms, ...
A study published in the Journal of Diabetes and its Complications found that older adults with diabetes are more likely to ...
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...